|
|
Vaccine Detail
|
Multipeptide Vaccine S-588210 |
| Vaccine Information |
- Vaccine Name: Multipeptide Vaccine S-588210
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007426
- Type: Other
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- LY6K
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- IGF2BP3
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- NUF2
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- DEPDC1
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- KIF20B
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Description: A cancer vaccine composed of a combination of the injectable formulations S-488210, which contains the three HLA-A*02:01-restricted peptides up-regulated lung cancer 10 (lymphocyte antigen 6K; LY6K; URLC10), cell division cycle-associated protein 1 (kinetochore protein Nuf2; NUF2; CDCA1) and insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3; KOC1) and S-488211, which contains the two HLA-A*02:01-restricted peptides DEP domain-containing protein 1A (DEPDC1) and M-phase phosphoprotein 1 (kinesin-like protein KIF20B; MPHOSPH1), with potential immunostimulatory and antitumor activities. Upon administration, multipeptide vaccine S-588210 may stimulate a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing KOC1, CDCA1, URLC10, DEPDC1 or MPHOSPH1 peptides, resulting in tumor cell lysis and decreased tumor growth. (NCIT_C125692).
|
| Host Response |
|
|
| References |
NCIT_C125692: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C125692]
|
|
